SHIELD THERAPEUTICS PLC (STX) — Q3 Trading Update

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SHIELD THERAPEUTICS PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll, And I'd now like to hand you over to the management team from SHIELD THERAPEUTICS PLC. Anders, good afternoon, sir. Good afternoon, and thank you so much, and welcome, everybody. Thank you for joining us, for today's presentation about SHIELD THERAPEUTICS. Santos, who is our CFO, and I Anders will present. The first part is a general part about the company. And for those of you who have followed us before, it is maybe a repetition. And then Santos will follow me with the recent q three trading update after a little while. So we can go to the next slide. This is the disclaimer, and I'll move into the actual presentation. So we at SHIELD THERAPEUTICS, we have one commercial product. It's called AccraFer in North America and Feracru in in rest of the world. And it is the only FDA, EMA, UK, and the Health Canada approved oral iron that's broadly indicated for adults suffering from iron deficiency or iron deficiency with anemia. This market is a is a large market because traditional oral irons is typically discontinued because of GI side effects such as stomach pain or constipation leading that patient stop therapy. I'll come back to that a little bit more in detail in a lit...